Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7783136rdf:typepubmed:Citationlld:pubmed
pubmed-article:7783136lifeskim:mentionsumls-concept:C0005456lld:lifeskim
pubmed-article:7783136lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:7783136lifeskim:mentionsumls-concept:C0023688lld:lifeskim
pubmed-article:7783136lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:7783136lifeskim:mentionsumls-concept:C1707689lld:lifeskim
pubmed-article:7783136lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:7783136pubmed:issue12lld:pubmed
pubmed-article:7783136pubmed:dateCreated1995-7-14lld:pubmed
pubmed-article:7783136pubmed:abstractTextNew melatonin-like agents were designed from the frameworks of 2,5-dimethoxyphenethylamine, an important structural moiety for the 5-HT receptor, and (2-methoxynaphthyl)-ethylamine. The compounds were synthesized by classical methods and evaluated in binding assays with chicken brain membranes using 2-[125I]iodomelatonin as the radioligand. Preliminary studies on the series of N-acyl-disubstituted phenethylamines showed the favorable role of the methoxy group in the ortho position of the side chain on the affinity for the receptor (Ki = 8 +/- 0.2 nM) for N-[2-(2-methoxy-5-bromophenyl)ethyl]propionamide (3o). This effect was confirmed in a series of the naphthalene derivatives, a bioisosteric moiety of the indole ring, and several potent ligands for melatonin binding sites were prepared such as N-[2-(2-methoxynaphthyl)ethyl]propionamide (4b) (Ki = 0.67 +/- 0.05 nM) and N-[2-(2,7-dimethoxynaphthyl)ethyl]cyclopropylformamide (Ki = 0.05 +/- 0.004 nM) (4k). Structure-activity relationships are discussed with regard to melatonin and bioisosteric naphthalenic compound 2. The Ki value for 4b was affected to a similar extent to that of melatonin by GTP-gamma-S or Mn2+ in competition experiments, suggesting an agonist profile for this compound.lld:pubmed
pubmed-article:7783136pubmed:languageenglld:pubmed
pubmed-article:7783136pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7783136pubmed:citationSubsetIMlld:pubmed
pubmed-article:7783136pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7783136pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7783136pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7783136pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7783136pubmed:statusMEDLINElld:pubmed
pubmed-article:7783136pubmed:monthJunlld:pubmed
pubmed-article:7783136pubmed:issn0022-2623lld:pubmed
pubmed-article:7783136pubmed:authorpubmed-author:ShenSSlld:pubmed
pubmed-article:7783136pubmed:authorpubmed-author:LangloisMMlld:pubmed
pubmed-article:7783136pubmed:authorpubmed-author:RenardPPlld:pubmed
pubmed-article:7783136pubmed:authorpubmed-author:SicsicSSlld:pubmed
pubmed-article:7783136pubmed:authorpubmed-author:AndrieuxJJlld:pubmed
pubmed-article:7783136pubmed:authorpubmed-author:DelagrangePPlld:pubmed
pubmed-article:7783136pubmed:authorpubmed-author:SerrasFFlld:pubmed
pubmed-article:7783136pubmed:authorpubmed-author:BrémontBBlld:pubmed
pubmed-article:7783136pubmed:authorpubmed-author:PoncetAAlld:pubmed
pubmed-article:7783136pubmed:authorpubmed-author:Mathé-Allainm...lld:pubmed
pubmed-article:7783136pubmed:issnTypePrintlld:pubmed
pubmed-article:7783136pubmed:day9lld:pubmed
pubmed-article:7783136pubmed:volume38lld:pubmed
pubmed-article:7783136pubmed:ownerNLMlld:pubmed
pubmed-article:7783136pubmed:authorsCompleteYlld:pubmed
pubmed-article:7783136pubmed:pagination2050-60lld:pubmed
pubmed-article:7783136pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:7783136pubmed:meshHeadingpubmed-meshheading:7783136-...lld:pubmed
pubmed-article:7783136pubmed:meshHeadingpubmed-meshheading:7783136-...lld:pubmed
pubmed-article:7783136pubmed:meshHeadingpubmed-meshheading:7783136-...lld:pubmed
pubmed-article:7783136pubmed:meshHeadingpubmed-meshheading:7783136-...lld:pubmed
pubmed-article:7783136pubmed:meshHeadingpubmed-meshheading:7783136-...lld:pubmed
pubmed-article:7783136pubmed:meshHeadingpubmed-meshheading:7783136-...lld:pubmed
pubmed-article:7783136pubmed:meshHeadingpubmed-meshheading:7783136-...lld:pubmed
pubmed-article:7783136pubmed:meshHeadingpubmed-meshheading:7783136-...lld:pubmed
pubmed-article:7783136pubmed:meshHeadingpubmed-meshheading:7783136-...lld:pubmed
pubmed-article:7783136pubmed:meshHeadingpubmed-meshheading:7783136-...lld:pubmed
pubmed-article:7783136pubmed:meshHeadingpubmed-meshheading:7783136-...lld:pubmed
pubmed-article:7783136pubmed:year1995lld:pubmed
pubmed-article:7783136pubmed:articleTitleDesign and synthesis of new naphthalenic derivatives as ligands for 2-[125I]iodomelatonin binding sites.lld:pubmed
pubmed-article:7783136pubmed:affiliationCNRS-BIOCIS, Faculté de Pharmacie, Châtenay-Malabry, France.lld:pubmed
pubmed-article:7783136pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:7783136lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7783136lld:pubmed